NGS Results Interpretation for Therapy Matching 2026 | Biomarker-to-Treatment Clinical Guide | CancerCareE

NOT a hospital • NOT a medical provider $0 patient fees • Always 200+ partner institutions across 8 countries

CLINICAL GUIDE • 2025-2026 STANDARDS

NGS Results Interpretation
for Therapy Matching

A Practical Clinical Guide. Translating Genomic Data into Actionable Treatment Pathways. The definitive biomarker-to-therapy matrix for referring oncologists.

ASCO/ESMO/NCCN Aligned Pan-Tumor Biomarkers Global Access Matrix

Executive Summary

The Death of "Organ-Based" Oncology

An NGS report is only as valuable as the clinician's ability to separate actionable drivers from genomic noise.This guide cuts through the bioinformatics complexity, providing a practical, evidence-based framework to match NGS findings with the most advanced targeted therapies, immunotherapies, and Antibody-Drug Conjugates (ADCs) available globally. It also highlights geographic disparities in drug approvals, showing you how to access therapies in China or Europe when the FDA has not yet approved them for your patient's specific biomarker.

ASCOESMONCCNCSCOFDANMPAClinicalTrials.gov

Part 1

The "Big Five" Pan-Tumor Biomarkers

These five biomarkers transcend organ boundaries. If your patient's NGS reports any of these, the treatment paradigm shifts immediately.

🧬 1. PD-L1 Expression

The Immunotherapy Gatekeeper. Look at the scoring algorithm: TPS (Tumor Proportion Score) for NSCLC — TPS ≥ 50% = single-agent Pembrolizumab. CPS (Combined Positive Score) for Gastric, Head & Neck, Cervical — CPS ≥ 5 or ≥ 10 dictates IO + Chemo.

🩺 Action: Match PD-L1 status to immunotherapy regimen based on cancer type and scoring algorithm.

💡 Clinical Pearl: PD-L1 score of 0 does not mean immunotherapy will fail, but it significantly lowers probability of success. Look for alternative IO combinations or clinical trials.

🧬 2. MSI-H / dMMR

The Universal IO Predictor. Microsatellite Instability-High or mismatch repair deficiency is the most robust biomarker for immune checkpoint inhibitors across all solid tumors.

🩺 Action: If MSI-H/dMMR is positive, Pembrolizumab or Dostarlimab is a Category 1 recommendation — regardless of organ of origin.

💡 Clinical Pearl: Test all colorectal and endometrial cancers for MSI. If tissue testing is equivocal, use a liquid biopsy NGS panel to confirm.

🧬 3. TMB (Tumor Mutational Burden)

Pan-Tumor IO Predictor. FDA-approved cutoff for Pembrolizumab: TMB-H (≥10 mut/Mb). Used when PD-L1 is negative or low, but the tumor has high mutational load.

🩺 Action: Use targeted panel TMB (e.g., FoundationOne CDx), not whole-exome sequencing TMB, to predict IO response.

💡 Clinical Pearl: TMB is highly assay-dependent. Ensure the NGS panel used is validated for TMB calculation.

🧬 4. BRCA1/2 and HRD

The PARP Inhibitor Triggers. BRCA mutations are actionable in pancreatic, prostate, and biliary tract cancers, not just breast and ovarian. Look for the broader HRD score.

🩺 Action: Match to PARP inhibitors (Olaparib, Talazoparib, Niraparib, Rucaparib).

💡 2025/2026 Update: The new frontier is combining PARP inhibitors with Immunotherapy or ADCs to overcome resistance.

🧬 5. HER2 (From 3+ to Ultra-Low)

The New Spectrum. The DESTINY trials shattered the binary view. We now recognize HER2-Low (IHC 1+ or IHC 2+/ISH-) and HER2-Ultra-Low.

🩺 Action: If NGS/IHC shows HER2-Low, the patient is eligible for Trastuzumab deruxtecan (T-DXd / Enhertu).

💡 The China Advantage: China leads with next-gen pan-HER ADCs like SHR-A1811 — equal efficacy, significantly lower pulmonary toxicity.

Part 2

Tumor-Specific Drivers (The "Must-Test" Matrix)

When a pan-tumor biomarker is negative, look for organ-specific driver mutations.

Cancer Type	Critical NGS Targets	Matched Therapy (Global Standard)
NSCLC (Adenocarcinoma)	EGFR, ALK, ROS1, BRAF V600E, KRAS G12C, MET ex14, RET, NTRK	Osimertinib, Alectinib, Entrectinib, Adagrasib, Tepotinib, Selpercatinib
Breast Cancer	PIK3CA, AKT1, PTEN, ESR1, BRCA1/2, HER2	Alpelisib, Capivasertib, Elacestrant, Olaparib, T-DXd
Gastric / GEJ	HER2, Claudin 18.2, FGFR2, MSI-H	Trastuzumab, Zolbetuximab (or CLDN18.2 CAR-T/ADC trials in China)
Biliary / Cholangio	FGFR2 fusions, IDH1, BRAF, HER2, NTRK	Pemigatinib, Ivosidenib, T-DXd (if HER2+)
Urothelial (Bladder)	FGFR3, ERBB2 (HER2), RB1, TP53	Erdafitinib, Enfortumab vedotin, Sacituzumab govitecan

Part 3

The NGS-to-Therapy Decision Tree

How to sequence your treatment decisions when the NGS report lands on your desk.

Is there a Level 1 Actionable Driver Mutation?

(e.g., EGFR, ALK, ROS1, BRCA, FGFR2) Tier 1

✅ YES: Initiate matched TKI or PARPi. Do NOT give immunotherapy first.❌ NO: Proceed to Step 2

Is the tumor "Immunologically Hot"?

(Check PD-L1 CPS/TPS, MSI-H/dMMR, TMB-H) Tier 1

✅ YES: Initiate Immunotherapy (single agent or IO + Chemo).❌ NO: Proceed to Step 3

Does the tumor express targetable surface antigens for ADCs?

(Check HER2 [even low], Trop-2, CLDN18.2, Nectin-4) Tier 2

✅ YES: Initiate matched ADC (e.g., T-DXd for HER2-Low, SG for Trop-2).❌ NO: Proceed to Step 4

No actionable targets found (The "Genomic Desert")

VUS / Unknown

Action: Do not force targeted therapy based on a VUS. Re-biopsy (Liquid or Tissue). Enroll in a Basket Trial or Compassionate Use program for novel agents (e.g., KRAS G12D inhibitors, solid tumor CAR-T in China).

Part 4

The Global Access Matrix

Navigating regulatory disparities. CancerCareE bridges the gap between what NGS says a patient needs, and what is actually available.

Biomarker / Target	USA / Europe Status	China (NMPA) Status	The CancerCareE Solution
HER2-Low (Breast/Gastric)	T-DXd approved; high cost, ILD risk	T-DXd available; SHR-A1811 (next-gen ADC) in trials	Match to SHR-A1811 trials if T-DXd fails or contraindicated
Claudin 18.2 (Gastric)	Zolbetuximab recently approved	CT041 (CAR-T) + multiple ADCs in Phase I/II	Fast-track CLDN18.2 CAR-T trials for R/R gastric cancer
KRAS G12C (NSCLC/CRC)	Sotorasib/Adagrasib approved	Domestic KRAS inhibitors in late-stage trials	Next-gen KRAS G12D/G12C inhibitors in Chinese Phase II trials
FGFR2/3 (Biliary/Urothelial)	Pemigatinib/Erdafitinib approved	Futibatinib + domestic FGFR TKIs subsidized	Rapid access to FGFR TKIs after Western TKI progression

Part 5

Pitfalls in NGS Interpretation

Three common clinical traps that local doctors must avoid.

1. Treating a VUS

⚠️ The Trap: NGS flags a "VUS" in EGFR or BRCA. Physician prescribes TKI or PARPi "just in case."

✅ The Reality: VUS means NO clinical evidence this mutation drives cancer or responds to drugs. Never base treatment on a VUS. Only treat Tier 1 or Tier 2 variants.

2. Confusing CHIP with Somatic Mutations

⚠️ The Trap: Liquid biopsy reports TP53 or DNMT3A. Physician assumes it's from the tumor.

✅ The Reality: These are often benign age-related blood cell mutations (CHIP). Always cross-reference liquid biopsy with matched WBC control or tissue biopsy.

3. Ignoring Liquid vs. Tissue Discordance

⚠️ The Trap: Tissue NGS negative for EGFR; liquid biopsy positive. Physician trusts tissue, gives chemo.

✅ The Reality: Liquid biopsies detect spatial heterogeneity. If liquid is positive, treat it as real. If liquid is negative, tissue biopsy is still required.

Part 6

Downloadable Clinical Assets

📥 NGS Therapy Matching Pocket Card (PDF)

A high-contrast, laminated-ready reference card mapping the top 20 actionable mutations directly to matched therapies, FDA/NMPA status, and standard dosing.

Download (Physician Verification)

📥 Liquid Biopsy Interpretation Checklist (PDF)

A step-by-step guide to differentiating true somatic mutations from CHIP, and handling low tumor fraction (ctDNA) results.